nach oben

Supportive Care in Cancer

Erschienen in:

01.06.2008 | Review Article

A “TNM” classification system for cancer pain: The Edmonton Classification System for Cancer Pain (ECS-CP)

verfasst von: Robin L. Fainsinger, Cheryl L. Nekolaichuk

Erschienen in: Supportive Care in Cancer | Ausgabe 6/2008

Einloggen, um Zugang zu erhalten

Abstract

Objective

The purpose of this paper is to provide an overview of the development of a “TNM“ cancer pain classification system for advanced cancer patients, the Edmonton Classification System for Cancer Pain (ECS-CP). Until we have a common international language to discuss cancer pain, understanding differences in clinical and research experience in opioid rotation and use remains problematic. The complexity of the cancer pain experience presents unique challenges for the classification of pain. To date, no universally accepted pain classification measure can accurately predict the complexity of pain management, particularly for patients with cancer pain that is difficult to treat.

Materials and methods

In response to this gap in clinical assessment, the Edmonton Staging System (ESS), a classification system for cancer pain, was developed. Difficulties in definitions and interpretation of some aspects of the ESS restricted acceptance and widespread use.

Result

Construct, inter-rater reliability, and predictive validity evidence have contributed to the development of the ECS-CP. The five features of the ECS-CP—Pain Mechanism, Incident Pain, Psychological Distress, Addictive Behavior and Cognitive Function—have demonstrated value in predicting pain management complexity.

Conclusion

The development of a standardized classification system that is comprehensive, prognostic and simple to use could provide a common language for clinical management and research of cancer pain. An international study to assess the inter-rater reliability and predictive value of the ECS-CP is currently in progress.

Nur mit Berechtigung zugänglich

Agency for Health Care Policy and Research (1994) Management of cancer pain: adults. Am J Hosp Pharm 51:1643–1656

Arner S, Meyerson BA (1988) Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 33:11–23PubMedCrossRef

Arner S (1998) Pain analysis in prediction of treatment outcome. Acta Anaesth Scand Suppl 113:24–28CrossRef

Boisvert M, Cohen SR (1995) Opioid use in advanced malignant disease: why do different centres use vastly different doses? A plea for standardized reporting. J Pain Symptom Manage 10:632–638PubMedCrossRef

Bruera E, Fainsinger R, Spachynski K et al (1995) Clinical efficacy and safety of a novel controlled-release morphine suppository and subcutaneous morphine in cancer pain: a randomized evaluation. J Clin Oncol 13:1520–1527PubMed

Bruera E, Macmillan K, Hanson J, MacDonald RN (1989) The Edmonton staging system for cancer pain: preliminary report. Pain 37:203–209PubMedCrossRef

Bruera E, Moyano J, Seifert L, Fainsinger RL et al (1995) The frequency of alcoholism among patients with pain due to terminal cancer. J Pain Symptom Manage 10:599–603PubMedCrossRef

Bruera E, Schoeller T, Wenk R et al (1995) A prospective multicenter assessment of the Edmonton staging system for cancer pain. J Pain Symptom Manage 10:348–355PubMedCrossRef

Bruera E, Sloan P, Mount B et al (1996) A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain. Canadian Palliative Care Clinical Trials Group. J Clin Oncol 14:1713–1717PubMed

10.

Bruera E, Watanabe S, Fainsinger RL et al (1995) Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain. Pain 62:141–146PubMedCrossRef

11.

Caraceni A, Portenoy RK (1991) An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain 82:263–274CrossRef

12.

Caraceni A (1996) Clinicopathologic correlates of common cancer pain syndromes. Hematol Oncol Clin North Am 10:57–58PubMedCrossRef

13.

De Stoutz ND, Bruera E, Suarez-Almazor M (1995) Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 10:378–384PubMedCrossRef

14.

Ernst DS, Brasher P, Hagen N et al (1997) A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symptom Manage 13:319–326PubMedCrossRef

15.

Fainsinger RL, Lowe S, Nekolaichuk C, Lawlor P (2006) Is pain intensity predictive for complexity of Cancer Pain? Palliat Med 20(3):269

16.

Fainsinger RL, Nekolaichuk CL, Lawlor PG, Neumann CM, Hanson J, Vigano A (2005) A multicentre validation study of the Revised Edmonton Staging System for classifying cancer pain in advanced cancer patients. J Pain Symptom Manage 29:224–237PubMedCrossRef

17.

Fainsinger RL, Nekolaichuk CL, Lawlor PG, Neumann CM. Edmonton classification system for cancer pain (ECS-CP). http://www.palliative.org/PC/Clinicalinfo/AssessmentToolsIDX.html

18.

Fainsinger RL, Toro R (1998) Opioids, confusion in opioid rotation. Palliat Med 12:463–464PubMedCrossRef

19.

Foley K (2000) Pain assessment and cancer pain syndromes. In: Doyle D, Hanks G, MacDonald N (eds) Oxford textbook of palliative medicine. Oxford University Press, Oxford, pp 310–331

20.

Hanks G, Portenoy RK, MacDonald N et al (2000) Difficult pain problems. In: Doyle D, Hanks G, MacDonald N (eds) Oxford textbook of palliative medicine. Oxford University Press, Oxford, pp 454–477

21.

Hwang S, Chang V, Kasimis B (2003) Cancer breakthrough pain characteristics and responses to treatment at VA Medical Centre. Pain 101:55–64PubMedCrossRef

22.

Hwang SS, Chang VT, Fairclough DL et al (2002) Development of a cancer pain prognostic scale. J Pain Symptom Manage 24(4):366–378PubMedCrossRef

23.

Jadad AR, Carroll D, Glynn CJ et al (1992) Morphine responsiveness of chronic pain: double-blind randomized crossover study with patient-controlled analgesia. Lancet 339:1367–1371PubMedCrossRef

24.

Kaiko RF, Wallenstein SL, Rogers AG et al (1982) Narcotics in the elderly. Med Clin North Am 66:1079–1089PubMed

25.

Lawlor P, Walker P, Bruera E et al (1997) Severe opioid toxicity and somatization of psychosocial distress in a cancer patient with a background of chemical dependence. J Pain Symptom Manage 13:356–361PubMedCrossRef

26.

Levy MH (1996) Pharmacologic treatment of cancer pain. New Engl J Med 335:1124–1132PubMedCrossRef

27.

Lowe S, Nekolaichuk C, Fainsinger R, Lawlor P (2008) Should the rate of opioid dose escalation be included as a factor in a Cancer Pain Classification System? J Pain Symptom Manage 35(1):51–57PubMedCrossRef

28.

Lutfy K, Yoburn BC (1991) The role of opioid receptor density in morphine tolerance. J Pharmacol Exp Ther 256:575–580PubMed

29.

Mercadante S, Casuccio A, Pumo S et al (2000) Factors influencing the opioid response in advanced cancer patients with pain followed at home: The effects of age and gender. Support Care in Cancer 8:123–130CrossRef

30.

Mercadante S, Fulfaro F, Casuccio A et al (1999) Investigation of an opioid response categorization in advanced cancer patients. J Pain Symptom Manage 18:347–352PubMedCrossRef

31.

Nekolaichuk C, Fainsinger R, Lawlor P (2005) A validation study of a pain classification system for advanced cancer patients using content experts: the Edmonton classification system for cancer pain. Palliat Med 19(6):466–476PubMedCrossRef

32.

Otis-Green S, Sherman R, Perez M et al (2002) An integrated psychosocial-spiritual model for cancer pain management. Cancer Pract 10(suppl 1):S58–S64PubMedCrossRef

33.

Passik SD, Portenoy RK, Ricketts PL (1998) Substance abuse issues in cancer patients. Part 1: Prevalence and diagnosis.. Oncology 12:517–521PubMed

34.

Passik SD, Portenoy RK, Ricketts PL (1998) Substance abuse issues in cancer patients. Part 2: Evaluation and treatment. Clin Tech Small Anim Pract 13:65–69CrossRef

35.

Passik SD, Theobald DE (2000) Managing addiction in advanced cancer patients: why bother? J Pain Symptom Manage 19:229–234PubMedCrossRef

36.

Piccirillo OJ, Feinstein A (1996) Clinical symptoms and co-morbidity: significance for the prognostic classification of cancer. Cancer 77:834–842PubMedCrossRef

37.

Portenoy RK, Foley KM, Inturrisi CE (1990) The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 43:273–286PubMedCrossRef

38.

Portenoy RK, Lesage P (1999) Management of cancer pain. Lancet 353:1695–1700PubMedCrossRef

39.

Portenoy RK, Payne D, Jacobsen P (1999) Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81:129–134PubMedCrossRef

40.

Sellers AH (1971) The clinical classification of malignant tumors: the TNM system. CMAJ 105:836–843

41.

South SM, Smith MT (2001) Analgesic tolerance to opioids. Pain 9(5):1–4

42.

Sutton LM, Porter LS, Keefe FJ (2002) Cancer pain at the end of life: a biopsychosocial perspective. Pain 99:5–10PubMedCrossRef

43.

Ventafridda V, Tamburini M, Caraceni A, De Conno F, Naldi F (1987) A validation study of the WHO method for cancer pain relief. Cancer 59:850–56PubMedCrossRef

44.

Woolf CJ, Decosterd I (1999) Implications of recent advances in the understanding of pain pathophysiology for the assessment of pain in patients. Pain Suppl 6:S141–S147CrossRef

45.

Zaza C, Baine N (2002) Cancer pain and psychosocial factors: a critical view of the literature. J Pain Symptom Manage 24:526–542PubMedCrossRef

46.

Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA (1995) Validation of the World Health Organization guidelines for cancer pain relief: a 10-year retrospective study. Pain 63:65–76PubMedCrossRef

Titel: A “TNM” classification system for cancer pain: The Edmonton Classification System for Cancer Pain (ECS-CP)
verfasst von: Robin L. Fainsinger
Cheryl L. Nekolaichuk
Publikationsdatum: 01.06.2008
Verlag: Springer-Verlag
Erschienen in: Supportive Care in Cancer / Ausgabe 6/2008
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-008-0423-3

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

A “TNM” classification system for cancer pain: The Edmonton Classification System for Cancer Pain (ECS-CP)

Abstract

Objective

Materials and methods

Result

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Objective

Materials and methods

Result

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2008

Frequency of side effects in outpatient cancer care and their influence on patient satisfaction—a prospective survey using the PASQOC® questionnaire

Abstracts of the 2008 international MASCC/ISOO symposium

Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib

A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer

Pulmonary MRI—a new approach for the evaluation of febrile neutropenic patients with malignancies

Specialized palliative care services are associated with improved short- and long-term caregiver outcomes

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie